DE69433518D1 - Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert - Google Patents

Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert

Info

Publication number
DE69433518D1
DE69433518D1 DE69433518A DE69433518A DE69433518D1 DE 69433518 D1 DE69433518 D1 DE 69433518D1 DE 69433518 A DE69433518 A DE 69433518A DE 69433518 A DE69433518 A DE 69433518A DE 69433518 D1 DE69433518 D1 DE 69433518D1
Authority
DE
Germany
Prior art keywords
repellent
nucleic acid
tumor
precursor
acid coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433518A
Other languages
English (en)
Other versions
DE69433518T4 (de
DE69433518T2 (de
Inventor
Vincent Brichard
Pel Aline Van
Catia Traversari
Thomas Wolfel
Thierry Boon-Falleur
Plaen Etienne De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Application granted granted Critical
Publication of DE69433518D1 publication Critical patent/DE69433518D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69433518A 1993-03-18 1994-03-09 Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert Expired - Lifetime DE69433518D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1994/002487 WO1994021126A1 (en) 1993-03-18 1994-03-09 Nucleic acid coding for a tumor rejection antigen precursor

Publications (1)

Publication Number Publication Date
DE69433518D1 true DE69433518D1 (de) 2004-03-04

Family

ID=21867896

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69433518A Expired - Lifetime DE69433518D1 (de) 1993-03-18 1994-03-09 Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE69433518T Expired - Lifetime DE69433518T4 (de) 1993-03-18 1994-03-09 Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69433518T Expired - Lifetime DE69433518T4 (de) 1993-03-18 1994-03-09 Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert

Country Status (17)

Country Link
US (2) US5620886A (de)
EP (1) EP0690675B1 (de)
JP (1) JP3433322B2 (de)
CN (1) CN1072719C (de)
AT (1) ATE258379T1 (de)
AU (1) AU675707B2 (de)
CA (1) CA2158446C (de)
DE (2) DE69433518D1 (de)
DK (1) DK0690675T5 (de)
ES (1) ES2210252T3 (de)
FI (1) FI954360A0 (de)
NO (1) NO953601L (de)
NZ (1) NZ263348A (de)
PT (1) PT690675E (de)
TW (1) TW442568B (de)
WO (1) WO1994021126A1 (de)
ZA (1) ZA941812B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (en) * 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
CA2258564A1 (en) * 1996-06-25 1997-12-31 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
EP0970206B1 (de) 1997-01-27 2008-07-23 Ludwig Institute For Cancer Research Lage-1 tumor-assozierte nukleinsäuren
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
CA2318979A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Antigen-specific cells, methods of generating these cells and uses thereof
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
EP1222274A2 (de) 1999-10-19 2002-07-17 Ludwig Institute For Cancer Research Vom mage-12 abgeleitete antigene peptide und deren verwendungen
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006009920A2 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101057145B (zh) 2004-06-23 2014-10-22 得克萨斯系统大学评议会 使用双粒子复合体检测生物分子的方法和组合物
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
NZ587601A (en) 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
EP2371850A3 (de) 2005-06-17 2012-08-01 Mannkind Corporation Epitopanaloge
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
MX2009012635A (es) * 2007-05-23 2012-09-13 Mannkind Corp Vectores multicistronicos y metodos para su diseño.
DK2224954T3 (en) 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
EP3268037B1 (de) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
EP3377532B1 (de) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antikörper gegen glucocorticoidinduzierten tumornekrosefaktorrezeptor (gitr) und verwendungen davon
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
ES2210252T3 (es) 2004-07-01
DK0690675T3 (da) 2004-06-01
PT690675E (pt) 2004-06-30
NO953601D0 (no) 1995-09-13
NO953601L (no) 1995-10-31
TW442568B (en) 2001-06-23
ATE258379T1 (de) 2004-02-15
AU675707B2 (en) 1997-02-13
ZA941812B (en) 1994-10-13
EP0690675A1 (de) 1996-01-10
DE69433518T4 (de) 2009-07-23
CA2158446A1 (en) 1994-09-29
FI954360A (fi) 1995-09-15
CA2158446C (en) 2009-01-06
EP0690675A4 (de) 1998-12-23
US5620886A (en) 1997-04-15
NZ263348A (en) 1996-06-25
AU6399394A (en) 1994-10-11
FI954360A0 (fi) 1995-09-15
WO1994021126A1 (en) 1994-09-29
JP3433322B2 (ja) 2003-08-04
EP0690675B1 (de) 2004-01-28
CN1072719C (zh) 2001-10-10
CN1093406A (zh) 1994-10-12
DK0690675T5 (da) 2008-11-17
DE69433518T2 (de) 2004-06-24
US5854203A (en) 1998-12-29
JPH08507693A (ja) 1996-08-20

Similar Documents

Publication Publication Date Title
DE69433518D1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
ES2103751T3 (es) Procedimiento para la obtencion de oxetanonas.
ATE267254T1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
DE69013313T2 (de) Mehrstufenverfahren zur Herstellung von Hexafluorpropylen.
DE69129302T2 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
PT845032E (pt) Moleculas isoladas de acidos nucleicos peptidos que formam complexos com a molecula a2-alh do cph e suas aplicacoes
FI960268A (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
BR9812837A (pt) Processo para fazer um composto, e, composto
DE69008326D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
DE69604560D1 (de) Die herstellung von fluorinierten organischen verbindungen
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
DE69010171T2 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
DE69626789D1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
BR9808923A (pt) Composto, e, processo para fazer o mesmo
DE59309133D1 (de) Granulozytenbindende Antikörperkonstrukte, ihre Herstellung und Verwendung
DK1404844T3 (da) Fremgangsmåde til fremstilling af 2,4-dideoxyhexoser og 2,4,6-trideoxyhyxoser
ES2058067T3 (es) Proceso para la produccion de 2,6-didesoxi-2-fluoro-l-talopiranosa y sus derivados.
ES2148891T3 (es) Procedimiento para la fabricacion de 2-metil-2,4-diaminopentano.
EP0261459A3 (de) Neue N-Benzothiazolylamide
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted